Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report

Anat R. Tambur, Patricia Campbell, Frans H. Claas, Sandy Feng, Howard M. Gebel, Annette M. Jackson, Roslyn B. Mannon, Elaine F. Reed, Kathryn Tinckam, Medhat Askar, Anil Chandraker, Patricia P. Chang, Monica Colvin, Anthony Jake Demetris, Joshua M. Diamond, Anne I. Dipchand, Robert L. Fairchild, Mandy L. Ford, John Friedewald, Ronald G. GillDenis Glotz, Hilary Goldberg, Ramsey Hachem, Stuart Knechtle, Jon Kobashigawa, Deborah J. Levine, Joshua Levitsky, Michael Mengel, Edgar Milford, Kenneth A. Newell, Jacqueline G. O’Leary, Scott Palmer, Parmjeet Randhawa, John Smith, Laurie Snyder, Randall C. Starling, Stuart Sweet, Timucin Taner, Craig J. Taylor, Steve Woodle, Adriana Zeevi, Peter Nickerson

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation. The goals were to perform a critical review of biologically driven, state-of-the-art, clinical diagnostics literature and to provide clinical practice recommendations based on expert assessment of quality and strength of evidence. The results of the Sensitization in Transplantation: Assessment of Risk (STAR) meeting are summarized here, providing recommendations on the definition and utilization of HLA diagnostic testing, and a framework for clinical assessment of risk for a memory or a primary alloimmune response. The definitions, recommendations, risk framework, and highlighted gaps in knowledge are intended to spur research that will inform the next STAR Working Group meeting in 2019.

Original languageEnglish (US)
Pages (from-to)1604-1614
Number of pages11
JournalAmerican Journal of Transplantation
Volume18
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Group Processes
Histocompatibility
Transplantation
Antibodies
Heart-Lung Transplantation
Organ Transplantation
Liver Transplantation
Kidney Transplantation
Research

Keywords

  • alloantibody
  • clinical research/practice
  • clinical trial design
  • guidelines
  • histocompatibility
  • immunobiology
  • monitoring: immune
  • sensitization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Tambur, A. R., Campbell, P., Claas, F. H., Feng, S., Gebel, H. M., Jackson, A. M., ... Nickerson, P. (2018). Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 18(7), 1604-1614. https://doi.org/10.1111/ajt.14752

Sensitization in Transplantation : Assessment of Risk (STAR) 2017 Working Group Meeting Report. / Tambur, Anat R.; Campbell, Patricia; Claas, Frans H.; Feng, Sandy; Gebel, Howard M.; Jackson, Annette M.; Mannon, Roslyn B.; Reed, Elaine F.; Tinckam, Kathryn; Askar, Medhat; Chandraker, Anil; Chang, Patricia P.; Colvin, Monica; Demetris, Anthony Jake; Diamond, Joshua M.; Dipchand, Anne I.; Fairchild, Robert L.; Ford, Mandy L.; Friedewald, John; Gill, Ronald G.; Glotz, Denis; Goldberg, Hilary; Hachem, Ramsey; Knechtle, Stuart; Kobashigawa, Jon; Levine, Deborah J.; Levitsky, Joshua; Mengel, Michael; Milford, Edgar; Newell, Kenneth A.; O’Leary, Jacqueline G.; Palmer, Scott; Randhawa, Parmjeet; Smith, John; Snyder, Laurie; Starling, Randall C.; Sweet, Stuart; Taner, Timucin; Taylor, Craig J.; Woodle, Steve; Zeevi, Adriana; Nickerson, Peter.

In: American Journal of Transplantation, Vol. 18, No. 7, 01.07.2018, p. 1604-1614.

Research output: Contribution to journalArticle

Tambur, AR, Campbell, P, Claas, FH, Feng, S, Gebel, HM, Jackson, AM, Mannon, RB, Reed, EF, Tinckam, K, Askar, M, Chandraker, A, Chang, PP, Colvin, M, Demetris, AJ, Diamond, JM, Dipchand, AI, Fairchild, RL, Ford, ML, Friedewald, J, Gill, RG, Glotz, D, Goldberg, H, Hachem, R, Knechtle, S, Kobashigawa, J, Levine, DJ, Levitsky, J, Mengel, M, Milford, E, Newell, KA, O’Leary, JG, Palmer, S, Randhawa, P, Smith, J, Snyder, L, Starling, RC, Sweet, S, Taner, T, Taylor, CJ, Woodle, S, Zeevi, A & Nickerson, P 2018, 'Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report', American Journal of Transplantation, vol. 18, no. 7, pp. 1604-1614. https://doi.org/10.1111/ajt.14752
Tambur, Anat R. ; Campbell, Patricia ; Claas, Frans H. ; Feng, Sandy ; Gebel, Howard M. ; Jackson, Annette M. ; Mannon, Roslyn B. ; Reed, Elaine F. ; Tinckam, Kathryn ; Askar, Medhat ; Chandraker, Anil ; Chang, Patricia P. ; Colvin, Monica ; Demetris, Anthony Jake ; Diamond, Joshua M. ; Dipchand, Anne I. ; Fairchild, Robert L. ; Ford, Mandy L. ; Friedewald, John ; Gill, Ronald G. ; Glotz, Denis ; Goldberg, Hilary ; Hachem, Ramsey ; Knechtle, Stuart ; Kobashigawa, Jon ; Levine, Deborah J. ; Levitsky, Joshua ; Mengel, Michael ; Milford, Edgar ; Newell, Kenneth A. ; O’Leary, Jacqueline G. ; Palmer, Scott ; Randhawa, Parmjeet ; Smith, John ; Snyder, Laurie ; Starling, Randall C. ; Sweet, Stuart ; Taner, Timucin ; Taylor, Craig J. ; Woodle, Steve ; Zeevi, Adriana ; Nickerson, Peter. / Sensitization in Transplantation : Assessment of Risk (STAR) 2017 Working Group Meeting Report. In: American Journal of Transplantation. 2018 ; Vol. 18, No. 7. pp. 1604-1614.
@article{afda3320c4d049479edfeb088a40b11b,
title = "Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report",
abstract = "The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation. The goals were to perform a critical review of biologically driven, state-of-the-art, clinical diagnostics literature and to provide clinical practice recommendations based on expert assessment of quality and strength of evidence. The results of the Sensitization in Transplantation: Assessment of Risk (STAR) meeting are summarized here, providing recommendations on the definition and utilization of HLA diagnostic testing, and a framework for clinical assessment of risk for a memory or a primary alloimmune response. The definitions, recommendations, risk framework, and highlighted gaps in knowledge are intended to spur research that will inform the next STAR Working Group meeting in 2019.",
keywords = "alloantibody, clinical research/practice, clinical trial design, guidelines, histocompatibility, immunobiology, monitoring: immune, sensitization",
author = "Tambur, {Anat R.} and Patricia Campbell and Claas, {Frans H.} and Sandy Feng and Gebel, {Howard M.} and Jackson, {Annette M.} and Mannon, {Roslyn B.} and Reed, {Elaine F.} and Kathryn Tinckam and Medhat Askar and Anil Chandraker and Chang, {Patricia P.} and Monica Colvin and Demetris, {Anthony Jake} and Diamond, {Joshua M.} and Dipchand, {Anne I.} and Fairchild, {Robert L.} and Ford, {Mandy L.} and John Friedewald and Gill, {Ronald G.} and Denis Glotz and Hilary Goldberg and Ramsey Hachem and Stuart Knechtle and Jon Kobashigawa and Levine, {Deborah J.} and Joshua Levitsky and Michael Mengel and Edgar Milford and Newell, {Kenneth A.} and O’Leary, {Jacqueline G.} and Scott Palmer and Parmjeet Randhawa and John Smith and Laurie Snyder and Starling, {Randall C.} and Stuart Sweet and Timucin Taner and Taylor, {Craig J.} and Steve Woodle and Adriana Zeevi and Peter Nickerson",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/ajt.14752",
language = "English (US)",
volume = "18",
pages = "1604--1614",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Sensitization in Transplantation

T2 - Assessment of Risk (STAR) 2017 Working Group Meeting Report

AU - Tambur, Anat R.

AU - Campbell, Patricia

AU - Claas, Frans H.

AU - Feng, Sandy

AU - Gebel, Howard M.

AU - Jackson, Annette M.

AU - Mannon, Roslyn B.

AU - Reed, Elaine F.

AU - Tinckam, Kathryn

AU - Askar, Medhat

AU - Chandraker, Anil

AU - Chang, Patricia P.

AU - Colvin, Monica

AU - Demetris, Anthony Jake

AU - Diamond, Joshua M.

AU - Dipchand, Anne I.

AU - Fairchild, Robert L.

AU - Ford, Mandy L.

AU - Friedewald, John

AU - Gill, Ronald G.

AU - Glotz, Denis

AU - Goldberg, Hilary

AU - Hachem, Ramsey

AU - Knechtle, Stuart

AU - Kobashigawa, Jon

AU - Levine, Deborah J.

AU - Levitsky, Joshua

AU - Mengel, Michael

AU - Milford, Edgar

AU - Newell, Kenneth A.

AU - O’Leary, Jacqueline G.

AU - Palmer, Scott

AU - Randhawa, Parmjeet

AU - Smith, John

AU - Snyder, Laurie

AU - Starling, Randall C.

AU - Sweet, Stuart

AU - Taner, Timucin

AU - Taylor, Craig J.

AU - Woodle, Steve

AU - Zeevi, Adriana

AU - Nickerson, Peter

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation. The goals were to perform a critical review of biologically driven, state-of-the-art, clinical diagnostics literature and to provide clinical practice recommendations based on expert assessment of quality and strength of evidence. The results of the Sensitization in Transplantation: Assessment of Risk (STAR) meeting are summarized here, providing recommendations on the definition and utilization of HLA diagnostic testing, and a framework for clinical assessment of risk for a memory or a primary alloimmune response. The definitions, recommendations, risk framework, and highlighted gaps in knowledge are intended to spur research that will inform the next STAR Working Group meeting in 2019.

AB - The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation. The goals were to perform a critical review of biologically driven, state-of-the-art, clinical diagnostics literature and to provide clinical practice recommendations based on expert assessment of quality and strength of evidence. The results of the Sensitization in Transplantation: Assessment of Risk (STAR) meeting are summarized here, providing recommendations on the definition and utilization of HLA diagnostic testing, and a framework for clinical assessment of risk for a memory or a primary alloimmune response. The definitions, recommendations, risk framework, and highlighted gaps in knowledge are intended to spur research that will inform the next STAR Working Group meeting in 2019.

KW - alloantibody

KW - clinical research/practice

KW - clinical trial design

KW - guidelines

KW - histocompatibility

KW - immunobiology

KW - monitoring: immune

KW - sensitization

UR - http://www.scopus.com/inward/record.url?scp=85047449998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047449998&partnerID=8YFLogxK

U2 - 10.1111/ajt.14752

DO - 10.1111/ajt.14752

M3 - Article

C2 - 29603613

AN - SCOPUS:85047449998

VL - 18

SP - 1604

EP - 1614

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 7

ER -